Association of pretreatment anemia with pathological response and survival of breast cancer patients treated with neoadjuvant chemotherapy: A population-based study

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Zhu, Wenjie ^a   Xu, Binghe ^a  

^a CANCER HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; EPIRUBICIN; HEMOGLOBIN; PACLITAXEL; TRASTUZUMAB;

ADULT; AGED; ALL CAUSE MORTALITY; ANEMIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MASTECTOMY; MEDICAL RECORD REVIEW; MORTALITY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POPULATION RESEARCH; POSTOPERATIVE CARE; PREDICTIVE VALUE; PREOPERATIVE TREATMENT; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; SENTINEL LYMPH NODE BIOPSY; SURVIVAL TIME; TREATMENT RESPONSE; ADVERSE EFFECTS; BREAST NEOPLASMS; CHEMICALLY INDUCED; COMPLICATION; MIDDLE AGED; NEOADJUVANT THERAPY; PATHOLOGY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; STATISTICAL MODEL; SURVIVAL ANALYSIS; YOUNG ADULT;

ADULT; AGED; ANEMIA; BREAST NEOPLASMS; FEMALE; HUMANS; LOGISTIC MODELS; MIDDLE AGED; NEOADJUVANT THERAPY; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84942908299     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0136268     Document Type: Article

References (30)

1. Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med. 2004; 116 Suppl 7A:11-26.
2. Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer. 2001; 91:2214-2221. PMID: 11413508
3. Boehm DU, Lebrecht A, Schmidt M, Siggelkow W, Lindner C, Litz A, et al. Prognostic impact of haemoglobin levels in breast cancer. Anticancer Res. 2007; 27:1223-1226. PMID: 17465267
4. Zhang Y, Chen Y, Chen D, Jiang Y, Huang W, Ouyang H, et al. Impact of preoperative anemia on relapse and survival in breast cancer patients. BMC Cancer. 2014; 14:844. doi: 10.1186/1471-2407- 14-844 PMID: 25406979
5. Vaupel P, Thews O, Hoeckel M. Treatment resistance of solid tumors: role of hypoxia and anemia. Med Oncol. 2001; 18:243-259. PMID: 11918451
6. Harrison LB, Chadha M, Hill RJ, Hu K, Shasha D. Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist. 2002; 7:492-508. PMID: 12490737
7. Hu K, Harrison LB. Impact of anemia in patients with head and neck cancer treated with radiation therapy. Curr Treat Options Oncol. 2005; 6:31-45. PMID: 15610713
8. Grogan M, Thomas GM, Melamed I, Wong FL, Pearcey RG, Joseph PK, et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer. 1999; 86:1528-1536. PMID: 10526282
9. Dunphy EP, Petersen IA, Cox RS, Bagshaw MA. The influence of initial hemoglobin and blood pressure levels on results of radiation therapy for carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1989; 16:1173-1178. PMID: 2715066
10. Henke M, Sindlinger F, Ikenberg H, Gerds T, Schumacher M. Blood hemoglobin level and treatment outcome of early breast cancer. Strahlenther Onkol. 2004; 180:45-51. PMID: 14704844
11. Green SL, Giaccia AJ. Tumor hypoxia and the cell cycle: implications for malignant progression and response to therapy. Cancer J Sci Am. 1998; 4:218-223. PMID: 9689978
12. Dubsky P, Sevelda P, Jakesz R, Hausmaninger H, Samonigg H, Seifert M, et al. Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy. Clin Cancer Res. 2008; 14:2082-2087. doi: 10.1158/1078-0432.CCR-07-2068 PMID: 18381948
13. Bottini A, Berruti A, Brizzi MP, Bersiga A, Generali D, Allevi G, et al. Pretreatment haemoglobin levels significantly predict the tumour response to primary chemotherapy in human breast cancer. Br J Cancer. 2003; 89:977-982. PMID: 12966412
14. Beresford MJ, Burcombe R, Ah-See ML, Stott D, Makris A. Pre-treatment haemoglobin levels and the prediction of response to neoadjuvant chemotherapy in breast cancer. Clin Oncol (R Coll Radiol). 2006; 18:453-458.
15. Gilreath JA, Stenehjem DD, Rodgers GM. Diagnosis and treatment of cancer-related anemia. Am J Hematol. 2014; 89:203-212. doi: 10.1002/ajh.23628 PMID: 24532336
16. Wilson J, Yao GL, Raftery J, Bohlius J, Brunskill S, Sandercock J, et al. A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Assess. 2007; 11:1-202.
17. Thompson CA, Steensma DP. Pure red cell aplasia associated with thymoma: clinical insights from a 50-year single-institution experience. Br J Haematol. 2006; 135:405-407. PMID: 17032177
18. Pan SS, Pedersen L, Bachur NR. Comparative flavoprotein catalysis of anthracycline antibiotic. Reductive cleavage and oxygen consumption. Mol Pharmacol. 1981; 19:184-186. PMID: 6937729
19. Matthews NE, Adams MA, Maxwell LR, Gofton TE, Graham CH. Nitric oxide-mediated regulation of chemosensitivity in cancer cells. J Natl Cancer Inst. 2001; 93:1879-1885. PMID: 11752013
20. Sullivan R, Pare GC, Frederiksen LJ, Semenza GL, Graham CH. Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity. Mol Cancer Ther. 2008; 7:1961-1973. doi: 10.1158/1535-7163.MCT-08-0198 PMID: 18645006
21. Flamant L, Notte A, Ninane N, Raes M, Michiels C. Anti-apoptotic role of HIF-1 and AP-1 in paclitaxel exposed breast cancer cells under hypoxia. Mol Cancer. 2010; 9:191. doi: 10.1186/1476-4598-9-191 PMID: 20626868
22. Flamant L, Roegiers E, Pierre M, Hayez A, Sterpin C, De Backer O, et al. TMEM45A is essential for hypoxia-induced chemoresistance in breast and liver cancer cells. BMC Cancer. 2012; 12:391. doi: 10. 1186/1471-2407-12-391 PMID: 22954140
23. Vaupel P, Mayer A. Hypoxia and anemia: effects on tumor biology and treatment resistance. Transfus Clin Biol. 2005; 12:5-10. PMID: 15814285
24. Feldmann HJ. Oxygenation of human tumors-implications for combined therapy. Lung Cancer. 2001; 33 Suppl 1:77-83.
25. Kamby C, Sengelov L. Survival and pattern of failure following locoregional recurrence of breast cancer. Clin Oncol (R Coll Radiol). 1999; 11:156-163.
26. Aapro M, Moebus V, Nitz U, O'Shaughnessy J, Pronzato P, Untch M, et al. Safety and efficacy outcomes with erythropoiesis-stimulating agents in patients with breast cancer: a meta-analysis. Ann Oncol. 2014; doi: 10.1093/annonc/mdu579
27. Todaro M, Turdo A, Bartucci M, Iovino F, Dattilo R, Biffoni M, et al. Erythropoietin activates cell survival pathways in breast cancer stem-like cells to protect them from chemotherapy. Cancer Res. 2013; 73:6393-6400. doi: 10.1158/0008-5472.CAN-13-0248 PMID: 24008319
28. Hedley BD, Chu JE, Ormond DG, Beausoleil MS, Boasie A, Allan AL, et al. Recombinant human erythropoietin in combination with chemotherapy increases breast cancer metastasis in preclinical mouse models. Clin Cancer Res. 2011; 17:6151-6162. doi: 10.1158/1078-0432.CCR-10-3298 PMID: 21856770
29. Rodgers GM 3rd, Becker PS, Blinder M, Cella D, Chanan-Khan A, Cleeland C, et al. Cancer- and chemotherapy- induced anemia. J Natl Compr Canc Netw. 2012; 10:628-653. PMID: 22570293
30. Khorana AA, Francis CW, Blumberg N, Culakova E, Refaai MA, Lyman GH. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med. 2008; 168: 2377-2381. doi: 10.1001/archinte.168.21.2377 PMID: 19029504